Company profile for Syntis Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Syntis Bio is a clinical-stage biopharmaceutical company redefining oral therapy. We harness the small intestine's unique biology with our proprietary SYNT™ technology, a transient polymer coating that controls nutrient uptake and enhances drug delivery. Our lead program, SYNT-101, is a once-daily oral pill for obesity designed to mimic the metabolic benefits of gastric bypass surgery. We are leveraging this platform to deve...
Syntis Bio is a clinical-stage biopharmaceutical company redefining oral therapy. We harness the small intestine's unique biology with our proprietary SYNT™ technology, a transient polymer coating that controls nutrient uptake and enhances drug delivery. Our lead program, SYNT-101, is a once-daily oral pill for obesity designed to mimic the metabolic benefits of gastric bypass surgery. We are leveraging this platform to develop accessible and effective oral treatments for a wide range of conditions, from prevalent metabolic diseases to rare genetic disorders. Syntis Bio is headquartered in Boston.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
135 Morrissey Boulevard Ste 101A Boston, MA 02125
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250701704610/en/Syntis-Bio-Closes-%2438-Million-Financing-to-Accelerate-Oral-Therapies-for-Obesity-and-Rare-Diseases

BUSINESSWIRE
01 Jul 2025

https://www.businesswire.com/news/home/20250410377442/en/Syntis-Bio-Releases-New-Data-Supporting-Potential-of-SYNT-101-as-a-Once-Daily-Oral-Treatment-for-Obesity-at-European-Congress-on-Obesity-and-Weight-Management

BUSINESSWIRE
10 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty